ArticleAnnals of general psychiatry2026
Depression and apathy: examining an overlooked dimension.
Article in Annals of general psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApathy is a significant yet frequently overlooked aspect of Major Depressive Disorder (MDD), often confused with anhedonia, and with the potential to influence clinical outcomes and quality of life regardless of the severity of depressive symptoms. Despite its importance, the relationship between apathy and depression remains underrepresented in current research. This study aims to assess the prevalence of apathy in a sample of outpatients affected by MDD and to explore its clinical, cognitive, and functional correlates.
methodsOutpatients with MDD (n = 154) during a clinical stability phase have been assessed using the Apathy Evaluation Scale-Clinician version (AES-C), Dimensional Apathy Scale (I-DAS), MADRS, BDI-II, MMSE, PANSS, EQ-5D-3 L, and CGI-S. Patients were categorized into two groups according to the presence/absence of apathy (AES-C score ≥ 42). Groups comparison and a stepwise logistic regression were run to identify clinical differences between groups and the predictors of apathy.
resultsApathy was detected in 48% of the sample. Patients with apathy scored higher on depression scales, had lower cognitive performance, more negative and general psychopathology, greater clinical severity, and reduced quality of life. Significant differences emerged in initiation and executive apathy. Logistic regression identified MADRS item 8 “inability to feel” and BDI-II item 12 “loss of interest” as the factors showing the strongest association with apathy.
conclusionApathy is a prevalent and clinically relevant feature in MDD, associated with greater psychopathology and functional impairment. Findings support the need to routinely assess apathy in clinical setting, even during symptomatic stability phases. Specific symptoms may serve as key markers for its identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.